Rationale, design, and baseline characteristics in Elixa, a long-term cardiovascular endpoint trial of Lixisenatide versus Placebo

Conclusion ELIXA will be the first trial to report the safety and efficacy of a GLP-1RA in people with T2DM and high CV-event risk.
Source: American Heart Journal - Category: Cardiology Source Type: research